Tech Company Financing Transactions
Illimis Therapeutics Funding Round
On 7/14/2025, Illimis Therapeutics announced $42 million in Series B financing from AJU IB Investment, Company K Partners and DAYLI Partners.
Transaction Overview
Company Name
Announced On
7/14/2025
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development of GAIA-based Alzheimer's Disease therapeutics, expand its target indications to various immune disorders, and broaden its pipeline of potential blockbuster drug candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
18, Heolleung-ro 569-gil, Gangnam-gu 2F&3F
Seoul, 06376
Republic of Korea
Seoul, 06376
Republic of Korea
Phone
Website
Email Address
Overview
We translate cutting edge science into innovative medicine. A company that constantly takes on challenges to translate cutting-edge science into medicines for incurable disease based on fusion protein platform technologies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sanghoon Park
Browse more venture capital transactions:
Prev: 7/14/2025: Opper AI venture capital transaction
Next: 7/14/2025: Dextall venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs